NCT01494740已完成2 期
Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants
Shanghai Institute Of Biological Products1 个研究点 分布在 1 个国家目标入组 312 人开始时间: 2009年12月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 312
- 试验地点
- 1
- 主要终点
- Hemagglutination inhibition antibody titer
研究概览
简要总结
The aim of this study is to investigate the immunogenicity and safety of the inactivated split-virion vaccine in infants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 6 Months 至 36 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy infants aged between 6 and 35 months
- •full-term birth with birth weight above 2,500 grams
- •Subject and parent/legal representative should be present at all scheduled visits and to obey all trial procedures
排除标准
- •Volunteers in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination
- •Volunteers allergic to ingredient of vaccine composition (can be checked from vaccination history), especially to egg
- •History of progressive or severe neurologic disorder
- •Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
- •Known or suspected impairment/alteration of immune function, for example receiving immunosuppressive therapy or receiving blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation
- •Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
- •Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
- •History of thyroidectomy or thyroid disease that required medication within the past 12 months
- •Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years
- •Guillain-Barre Syndrome
- •Self-reported seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C
- •Any other vaccines or immunoglobulin preparation within 1 weeks prior to enrollment
- •Axillary temperature ≥ 38.0 degrees Celsius within 3 days of intended study vaccination
- •Any conditions may influence the evaluation
结局指标
主要结局
Hemagglutination inhibition antibody titer
时间窗: Days 35
次要结局
- Occurrence of solicited local and systemic adverse events after vaccination(Day0-42)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant SubjectsOrthomyxoviridae InfectionsInfluenzaNCT00606359Sanofi Pasteur, a Sanofi Company62
进行中（未招募）
不适用
Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route)EUCTR2008-000943-33-GBSanofi Pasteur SA
进行中（未招募）
不适用
Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route)Vaccination of healthy subjects aged 18 to 60 years (i.e. to the day before the 61st birthday) or 61 years or above (from the day of the 61st birthday) on the day of inclusion with one dose of the new formulation of the influenza vaccine for the 2007-2008 Northern Hemisphere season.EUCTR2007-000752-14-GBSanofi Pasteur SA
进行中（未招募）
1 期
Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2006-2007 Formulation (Intramuscular Route) - N/AEUCTR2006-000671-15-GBSanofi Pasteur SA120
已完成
2 期
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly SubjectsOrthomyxoviridae InfectionMyxovirus InfectionInfluenzaNCT00388583Sanofi817